STALLERGENES : 1st Quarter 2010 : Sustained 13% Growth

Friday, April 16, 2010 General News J E 4

Consolidated sales for the 1st quarter grew by 13% to EUR 63.3 million(up 15% in 2009). Foreign exchange effects were positive by EUR 0.3 million.

This growth confirms the supremacy of SLIT over SCIT, respectivelyposting growth of 17% and a decline of 8% over the 1st quarter. SLIT nowaccounts for 87% of the laboratory's sales.

The analysis by geographic region highlights satisfactory growth in allmarkets, with the "Other EU countries" region continuing to drive Groupgrowth under the effect of the significant increase in Oralair(R) sales inGermany.

Changes in financial position and significant transactions and events ofthe quarter

The financial position improved: cash net of debt was largely positive at31 March, whereas it was negative at the same time last year.

Preliminary results of the Oralair(R) grasses trial in the US should beobtained and released before the end of April.

Outlook for the current financial year

The good first quarter results confirmed the guidance for full-year salesgrowth in excess of 8%, featuring further improvement in profit margins.

About Stallergenes

Stallergenes is a European biopharmaceutical laboratory specialising intreatments by immunotherapy for the prevention and treatment ofallergy-related respiratory conditions, such as rhino conjunctivitis,rhinitis and allergic asthma. Stallergenes is ranked seventh among Frenchpharmaceutical laboratories. A pioneer and a leader in immunotherapytreatments by sublingual administration, Stallergenes dedicates more than 20%(gross) of its sales to its Research and Development activities, which areprimarily directed at developing a new therapeutic range enabling theprovision of immunotherapy treatments by sublingual tablets.

Stallergenes realised 2009 sales of EUR 193 million, with over 500,000patients treated with Stallergenes desensitisation products.

For further financial information, please visit our website:http://www.stallergenes.comANTONY, France, April 15, 2010 /PRNewswire-FirstCall/ -- EURm 2009 09/08 2010 10/09 EURm %Sales Var.% EURm %Sales Var.% Southern Europe 41.8 74 10 46.9 74 12 (1) Other EU countries 12.7 23 36 14.6 23 15 Other markets 1.7 3 0 1.8 3 8 SLIT 47.2 84 16 55.0 87 17 SCIT 6.9 12 11 6.3 10 (8) Other products 2.1 4 11 2.0 3 (6) Total Q1 sales 56.2 100 15 63.3 100 13

SOURCE Stallergenes


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Avalere and The SCAN Foundation Unveil First-of-it...
Scottsdale Healthcare Hospitals Mark Earth Day Cel...